Abstract:
The rapid spread of SARS-CoV-2 led to the necessity of developing diagnostic tests for rapid virus detection. Many commercial platforms have appeared and have been approved for this purpose. In this study, 95 positive and 5 negative retrospective samples were analyzed by 4 different commercial RT-qPCR kits (TaqMan 2019nCoV Assay, Allplex™SARS-COV-2 Assay, FTD SARS-COV-2 Assay and qCOVID-19). The Hologic Aptima SARS-COV-2 and the Clart-COVID-19 system were also tested. serial dilutions of SARS-COV-2 standard control were included for sensitivity analysis. Among the qPCR tested qCOVID19 and Allplex™SARS-COV-2 Assay were both able to detect all the clinical samples included in the study. All four qPCR evaluated showed high sensitivity for samples with Ct<33. Clart-COVID-19 microarrays detected all samples and controls used in this study whereas Hologic Aptima Panther failed with one of the clinical samples. However, the main problem with this system was the number of invalidated samples despite avoiding the use of medium with guanidine isothiocyanate as recommended by the manufacturer. All the techniques tested were of value for SARS-CoV-2 detection.
摘要:
SARS-CoV-2的迅速传播导致开发用于快速病毒检测的诊断测试的必要性。许多商业平台已经出现并已被批准用于此目的。在这项研究中,通过4种不同的商业RT-qPCR试剂盒(TaqMan2019nCoV测定,Allplex™SARS-COV-2检测,FTDSARS-COV-2测定和qCOVID-19)。还测试了HologicAptimaSARS-COV-2和Clart-COVID-19系统。纳入SARS-COV-2标准对照的系列稀释液进行敏感性分析.在测试的qPCR中,qCOVID19和Allplex™SARS-COV-2测定均能够检测包括在研究中的所有临床样品。所评估的所有四个qPCR显示出对于Ct<33的样品的高灵敏度。Clart-COVID-19微阵列检测到本研究中使用的所有样品和对照,而HologicAptimaPanther在其中一个临床样品中失败。然而,该系统的主要问题是无效样品的数量,尽管按照制造商的建议避免使用含有异硫氰酸胍的培养基。所有测试的技术都对SARS-CoV-2检测具有价值。